194 related articles for article (PubMed ID: 11347136)
1. [Fluvastatin].
Teramoto T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():587-91. PubMed ID: 11347136
[No Abstract] [Full Text] [Related]
2. [Type 2 diabetic: risk same as after infarct. With LDL not only the quantity counts].
MMW Fortschr Med; 2004 Jun; 146(24):4. PubMed ID: 15366509
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Leitersdorf E; Muratti EN; Eliav O; Peters TK
Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin.
Corsini A; Pazzucconi F; Pfister P; Paoletti R; Sirtori CR
Lancet; 1996 Dec; 348(9041):1584. PubMed ID: 8950895
[No Abstract] [Full Text] [Related]
5. [LDL cholesterol--why lower and lower?].
Müller-Wieland D; Kotzka J
MMW Fortschr Med; 2007 May; 149(22):28-30. PubMed ID: 18069223
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin for lowering cholesterol.
Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137
[No Abstract] [Full Text] [Related]
7. [60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
MMW Fortschr Med; 2001 Nov; 143(44):60. PubMed ID: 11732408
[No Abstract] [Full Text] [Related]
8. Fluvastatin: what is the evidence?
Bagg W; Braatvedt G
N Z Med J; 1997 Aug; 110(1050):321-2. PubMed ID: 9315035
[No Abstract] [Full Text] [Related]
9. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
10. [Controlling LDL cholesterol from 2 sides. "I have never seen such low LDL values"].
MMW Fortschr Med; 2003 May; 145(20):59. PubMed ID: 12822234
[No Abstract] [Full Text] [Related]
11. The use over time of statins in coronary patients in an Italian tertiary referral center.
Gaspardone A; Proietti I; Altamura L; Tomai F; Versaci F; Crea F; Chiariello L; Gioffrè PA
Ital Heart J; 2001 Nov; 2(11):848-53. PubMed ID: 11770871
[TBL] [Abstract][Full Text] [Related]
12. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
13. In brief: Zetia and Vytorin: the ENHANCE study.
Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
[No Abstract] [Full Text] [Related]
14. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
[TBL] [Abstract][Full Text] [Related]
15. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
Eliav O; Schurr D; Pfister P; Friedlander Y; Leitersdorf E
Am J Cardiol; 1995 Jul; 76(2):76A-79A. PubMed ID: 7604804
[TBL] [Abstract][Full Text] [Related]
16. A clinical focus on statins.
Auer J; Eber B
Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
[TBL] [Abstract][Full Text] [Related]
17. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
18. [Hyperlipidemia: decreasing lipid values and effects of statins].
Mathes P
Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
[No Abstract] [Full Text] [Related]
19. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
Asberg A; Holdaas H
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
[TBL] [Abstract][Full Text] [Related]
20. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Milani M; Cimminiello C; Lorena M; Arpaia G; Soncini M; Bonfardeci G
Biomed Pharmacother; 1996; 50(6-7):269-74. PubMed ID: 8952866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
